Tags: type 1 diabetes, NHS, NICE, market access, Tzield, teplizumab

Sanofi's type 1 diabetes-delaying drug cleared for NHS use

By FieldPulse Editorial · June 23, 2026

NICE's draft guidance for Tzield gives Sanofi a meaningful UK access win for a therapy that can delay progression to symptomatic type 1 diabetes.

Sanofi's Tzield has been cleared for NHS use in England and Wales, giving the company a notable market-access milestone for one of the most unusual diabetes therapies now on the market.

Pharmaphorum reported that NICE issued final draft guidance supporting teplizumab for people aged eight and older with stage 2 type 1 diabetes, before they develop symptomatic disease.

This is important because Tzield is not another insulin-management story.

It is a disease-delaying therapy intended to push back progression to stage 3 type 1 diabetes and the start of insulin dependence.

In clinical testing, a one-time two-week infusion course delayed progression by roughly two to three years.

For FieldPulse purposes, this remains a brief because the decision is UK-only.

It does not change US access today.

But it does give Sanofi teams a real-world reimbursement reference point for a therapy that asks payers and providers to think differently about type 1 diabetes intervention.

NICE estimates around 1,100 people could be eligible in the first year, then about 820 in later years.

The practical signal for commercial and access teams is that a major public payer has accepted the value case for delaying onset rather than waiting for symptomatic disease.

That does not settle every market-access argument elsewhere, but it strengthens Sanofi's broader positioning around Tzield as a clinically meaningful and system-relevant product.